Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
Belgium (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      CD7 (M-T701) BV605
      Product Details
      Down Arrow Up Arrow


      BD®
      GP40; LEU-9; T-cell leukemia antigen; Tp40; TP41
      Human
      Mouse BALB/c IgG1, κ
      P-CLL and Jurkat Cells
      Flow cytometry
      5 µl
      IV T163
      924
      IVD


      Preparation And Storage

      The antibody reagent is stable until the expiration date shown on the label when stored at 2° to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.

      Show More blue down arrow Show Less blue up arrow
      664448 Rev. 1
      Antibody Details
      Down Arrow Up Arrow
      M-T701
      664448 Rev. 1
      Format Details
      Down Arrow Up Arrow
      BV605
      The BD Horizon Brilliant Violet™ 605 (BV605) dye is part of the BD Horizon Brilliant Violet™ family of dyes. This tandem fluorochrome is comprised of a BV421 donor with an excitation maximum (Ex Max) of 407-nm and an acceptor dye with an emission maximum (Em Max) at 605-nm. BV605, driven by BD innovation, is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 610-nm (e.g., a 610/20-nm bandpass filter). The acceptor dye can be excited by the yellow-green (561-nm) laser resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
      altImg
      BV605
      Violet 405 nm
      407 nm
      605 nm
      664448 Rev.1
      Citations & References
      Down Arrow Up Arrow

      Development References (15)

      1. Li Y, Wei J, Mao X, et al. Flow Cytometric Immunophenotyping Is Sensitive for the Early Diagnosis of De Novo Aggressive Natural Killer Cell Leukemia (ANKL): A Multicenter Retrospective Analysis. PLoS One. 2016; 11(8):e0158827. View Reference
      2. Bowen M. Kishimoto T, Kikutani H, von dem Borne AEGK, et al, ed. Leucocyte Typing VI: White Cell Differentiation Antigens. 1998:62–63.
      3. Centers for Disease Control and Prevention. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. Available: https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html March 12, 2019. View Reference
      4. Clinical and Laboratory Standards Institute. Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells. In: CLSI. CLSI, ed. CLSI document H43-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2007:1-81. View Reference
      5. Clinical and Laboratory Standards Institute. Collection of Diagnostic Venous Blood Specimens, 7th ed. In: CLSI. CLSI, ed. CLSI document GP41-A7. Wayne, PA: Clinical and Laboratory Standards Institute; 2017:1-85. View Reference
      6. Clinical and Laboratory Standards Institute. Protection of Laboratory Workers from Occupationally Acquired Infections. In: CLSI. CLSI, ed. CLSI document M29-A4. Wayne, PA: Clinical and Laboratory Standards Institute; 2014:1-133. View Reference
      7. Haycocks NG, Lawrence L, Cain JW, Zhao XF. Optimizing antibody panels for efficient and cost-effective flow cytometric diagnosis of acute leukemia.. Cytometry B Clin Cytom. 2011; 80(4):221-9. View Reference
      8. Haynes BF, Denning SM, Singer KH, Kurtzberg J. Ontogeny of T-cell precursors: a model for the initial stages of human T-cell development. Immunol Today. 1989; 10(3):87-91.
      9. Jackson AL, Warner NL. Rose NR, Friedman H, Fahey JL, ed. Manual of Clinical Laboratory Immunology 3rd ed. Washington, DC: American Society for Microbiology; 1986:226-235.
      10. Kroll MH. Evaluating interference caused by lipemia.. Clin Chem. 2004; 50(11):1968-9. View Reference
      11. Mady YH, Sayed NG, Zakaria MA, Sayed DM. Assessment of the use of 8-color flow cytometry in the diagnosis of acute leukemia. SECI Oncology. 2019; 7:8-20.
      12. Nikolac N. Lipemia: causes, interference mechanisms, detection and management.. Biochem Med (Zagreb). 2014; 24(1):57-67. View Reference
      13. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis.. Leukemia. 1996; 10(5):877-95. View Reference
      14. Stelzer GT, Marti G, Hurley A, McCoy P, Lovett EJ, Schwartz A. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures.. Cytometry. 1997; 30(5):214-30. View Reference
      15. Zhou Y, Jorgensen JL, Wang SA, et al. Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia.. Am J Clin Pathol. 2012; 138(5):744-50. View Reference
      View All (15) View Less
      664448 Rev. 1

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For In Vitro Diagnostics Use.

      Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.

      Website Feedback